Meghan Mcgarry, MD, MS

Dr. McGarry is a Pediatric Pulmonologist who researches cystic fibrosis. Her main focus is researching health disparities in cystic fibrosis, particularly in minorities. She is conducting a cohort study of lung function in Latinos/Hispanics with cystic fibrosis. She also does research in diversity in clinical trials in cystic fibrosis.

Dr. McGarry studied Biology at Whitworth College. She then attended University of Washington School of Medicine, working in many underserved regions from Alaska to Zambia. She completed her Pediatric residency at Rainbow Babies and Children's Hospital. She completed her Pediatric Pulmonary and Pediatric Clinical Pharmacology Fellowships at University of California San Francisco. She also completed her Masters in Clinical Research at University of California San Francisco.
Education
Masters Clinical Research, 2015 - , University of California San Francisco
Pediatric Pulmonology, 2015 - , University of California San Francisco
Pediatric Residency, 2012 - , Rainbow Babies and Children's Hospital
M.D., 2009 - , University of Washington
BS Biology, 2005 - , Whitworth College
Honors and Awards
  • K Boost Award, Cystic Fibrosis Foundation, 2020-2023
  • K23 Career Development Award, NHLBI, 2018-2023
  • Jane Addams Social Justice Award, UCSF, 2017
  • Harry Schwachman Cystic Fibrosis Clinical Scholar, Cystic Fibrosis Foundation, 2016-2019
  • ATS International Conference Pediatric Abstract Scholarship, American Thoracic Society, 2016
  • Walter Travel Grant, Breathe California, 2015
  • Best Research, Fellows Poster Presentation, California Thoracic Society, 2015
  • ATS International Conference Pediatric Abstract Scholarship, American Thoracic Society, 2014
  • Fellow’s Scholarship, California CF Consortium, 2014
  • Pediatric Clinical Pharmacology, Drug Action, and Pharmacogenetics T32, NICHD/NIGMS, 2013-2016
  • Fellow’s Scholarship, California CF Consortium, 2013
  • Resident Teacher of the Year, Rainbow Babies and Children’s Hospital, 2010
Websites
Publications
  1. Food insecurity and mental health during the COVID-19 pandemic in cystic fibrosis households.
  2. Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis.
  3. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.
  4. Early acquisition and conversion of Pseudomonas aeruginosa in Hispanic youth with cystic fibrosis in the United States.
  5. Outcomes of Children With Cystic Fibrosis Admitted to PICUs.
  6. Transparency and diversity in cystic fibrosis research.
  7. Triple Therapy for Cystic Fibrosis with a Phe508del CFTR Mutation.
  8. The demographics of adverse outcomes in cystic fibrosis.
  9. Identification of CFTR variants in Latino patients with cystic fibrosis from the Dominican Republic and Puerto Rico.
  10. Regional variations in longitudinal pulmonary function: A comparison of Hispanic and non-Hispanic subjects with cystic fibrosis in the United States.
  11. Pulmonary Metagenomic Sequencing Suggests Missed Infections in Immunocompromised Children.
  12. A genome-wide association and admixture mapping study of bronchodilator drug response in African Americans with asthma.
  13. An admixture mapping meta-analysis implicates genetic variation at 18q21 with asthma susceptibility in Latinos.
  14. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis.
  15. In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.
  16. Breastfeeding associated with higher lung function in African American youths with asthma.
  17. Minorities Are Underrepresented in Clinical Trials of Pharmaceutical Agents for Cystic Fibrosis.
  18. Obesity and bronchodilator response in black and Hispanic children and adolescents with asthma.
  19. The lung corps' approach to reducing health disparities in respiratory disease.
  20. Normalization of sweat chloride concentration and clinical improvement with ivacaftor in a patient with cystic fibrosis with mutation S549N.